摘要
盐酸埃罗替尼是一种小分子表皮生长因子酪氨酸激酶可逆抑制剂,通过抑制酪氨酸激酶的磷酸化,阻断信号传导,抑制肿瘤生长。临床前研究表明其对表皮生长因子酪氨酸激酶有抑制作用;临床研究显示该药对多种肿瘤有抗肿瘤活性,不良反应较轻,与化疗药物合用不增加毒性。2004年经FDA批准上市,用于一线化疗失败的局部晚期或转移性非小细胞肺癌的治疗。
Erlotinib （Tarceva） is an epidermal growth factor receptor （EGFR） tyrosine kinase inhibitor used in molecular targeted therapy. It is one of a new group of drugs that targets tiny flaws in the cell＇ s communication machinery. By inhibition of phosphorylation of tyrosine kinase, erlotinib blocks the EGFR tyrosine kinase protein in the cancer cell from getting a message that tells the cell to grow and divide. Clinical studies demonstrated that this small molecular agent has antitumor activities. US FDA approved erlotinib tablets for treatment of locally advanced or metastatic Non Small-Cell Lung Cancer （NSCLC） after failure of at least one prior chemotherapy regimen in 2004.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2005年第10期1227-1229,共3页
Chinese Journal of New Drugs
关键词
埃罗替尼
EGFR酪氨酸激酶抑制剂
肿瘤
erlotinib
epidermal growth factor receptor tyrosine kinase inhibitor
tumor
